| Literature DB >> 27069332 |
Hasan Kahveci1, Cüneyt Tayman2, Fuat Laloğlu3, Nazan Kavas3, Murat Ciftel4, Osman Yılmaz4, Esra Laloğlu5, Abdulah Erdil3, Hülya Aksoy5, Salih Aydemir6.
Abstract
Hemodynamically significant ductus arteriosus (hsPDA) may alter organ perfusion by interfering blood flow to the tissues. Therefore, in infants with hsPDA, hypoxia occurs in many tissues. In this study, we aimed to investigate the diagnostic significance of serum (ischemia-modified albumin) IMA levels as a screening tool for hsPDA, and its relation to the severity of the disease in the preterm neonates. For this purpose, seventy-two premature infants with gestation age <34 weeks were included in the study. Thirty premature infants with hsPDA were assigned as the study group and 42 premature infants without PDA were determined as the control group. Blood samples were collected before the treatment and 24 h after the treatment, and analyzed for IMA levels. IMA levels in the study group (1.26 ± 0.36 ABSU) were found to be significantly higher than control group (0.65 ± 0.12 ABSU) (p < 0.05). In infants with hsPDA, a positive correlation was found between IMA and PDA diameter (ρ = 0.876, p = 0.022), and LA/Ao ratio (ρ = 0.863, p = 0.014). The cut-off value of IMA for hsPDA was measured as 0.78 ABSU with 88.89 % sensitivity, and 90.24 % specificity, 85.71 % positive predictive, 92.5 % negative predictive value [area under the curve (AUC) = 0.96; p < 0.001]. The mean IMA value of the infants with hsPDA before treatment was 1.26 ± 0.36 ABSU, and the mean IMA value of infants after medical treatment was 0.67 ± 0.27 ABSU (p = 0.03). We concluded that IMA can be used as a marker for the diagnosis and monitoring of a successful treatment of hsPDA.Entities:
Keywords: Diagnosis; Ischemia-modified albumin; Newborn; Patent ductus arteriosus; Preterm
Year: 2015 PMID: 27069332 PMCID: PMC4820428 DOI: 10.1007/s12291-015-0523-z
Source DB: PubMed Journal: Indian J Clin Biochem ISSN: 0970-1915